Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

of docetaxel plus placebo.

In April, sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP® (aflibercept) in combination with the FOLFIRI chemotherapy regimen (folinic acid, 5-fluorouracil, and irinotecan) versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer. The full study results will be presented at an upcoming medical meeting.

In addition to VITAL and VELOUR, the program includes one Phase III trial and one Phase II trial, all of which are fully enrolled. An interim analysis of the VENICE Phase III study evaluating aflibercept as a first-line treatment for hormone-refractory metastatic prostate cancer in combination with docetaxel and prednisone is expected to be conducted by an Independent Data Monitoring Committee in mid 2011. Final results of VENICE are anticipated in 2012. Final results of the AFFIRM Phase II study, evaluating aflibercept as a first-line treatment in metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), are expected during the second half of 2011.

A pediatric hexavalent vaccine (DTP-HepB-Polio-Hib) entered Phase III.

Two compounds entered Phase II

  • SAR110894D, a selective oral H3 receptor antagonist for Alzheimer's disease
  • SAR231893/ REGN668 (partnership with Regeneron), a monoclonal antibody anti IL4-R developed for asthma

  • Two compounds entered Phase I

  • SAR156597, a potential first-in-class bi-specific IL4/IL13 antibody for the treatment of patients with idiopathic pulmonary fibrosis
  • SAR307746/REGN910 (partnership with Regeneron), is a fully human IgG1 monoclonal antibody directed against Ang2 entered Phase I in oncology

  • SSR125543, a CRF1 antagonist, did not meet its endpoint in Phase II trial in patients with de
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... NEW YORK , Aug. 1, 2014 ... Square Capital Management, L.P. today responded to the filing ... AGN ) in California.  The complaint makes baseless ... offer rules.  Allergan,s true purpose in ... shareholders, efforts to call a special meeting.  That purpose ...
    (Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
    (Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
    Breaking Medicine Technology:Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 660+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3
    ... Reportlinker.com announces that a new market research report ... Drug Markets in Europe ... and the strategies of major pharmaceutical companies ... in Europe remains problematic for the developers, although ...
    ... Urban League (NUL) and the League of United Latin American ... negotiations and come to an agreement with Walgreens on new ... Americans, especially in diverse and underserved communities, stand to lose ... In an open letter to Express Scripts, Marc H. ...
    Cached Medicine Technology:Orphan Drug Markets in Europe 2Orphan Drug Markets in Europe 3Orphan Drug Markets in Europe 4Orphan Drug Markets in Europe 5Orphan Drug Markets in Europe 6Orphan Drug Markets in Europe 7The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 2The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 3
    (Date:8/1/2014)... News) -- The U.S. Food and Drug Administration announced ... to help fight type 2 diabetes. Jardiance ... treatment regimens to control blood sugar levels in the ... the Office of Drug Evaluation II in the FDA,s ... agency statement. The FDA also recommended that Jardiance ...
    (Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
    (Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
    (Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
    (Date:8/1/2014)... Abington, PA (PRWEB) August 01, 2014 ... beneficial than bottle-feeding. A recent study conducted ... may not lag too far behind in terms of ... simply want to know what’s best for their baby. ... , According to Dr. Steven Shapiro , chair ...
    Breaking Medicine News(10 mins):Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3
    ... Flight West (AFW),awarded The Distinguished Pilot award to Oakland ... September 29th. Birely completed,37 Angel Flight West missions over ... in need whose non-emergency health care problems require that,they ... AFW volunteer,pilots, donates the cost of all the missions ...
    ... and audio web cast on October 9, 2007 --, BELLEVILLE, ON, Oct. 5 /PRNewswire-FirstCall/ - ... Agriculture,(USDA) comment on a field trial for its E. coli O157:H7 cattle vaccine,during a: ... Conference Call & Audio Web Cast ... Tuesday, October 9, 2007 ...
    ... National Center for Complementary and Alternative Medicine (NCCAM) ... Research on Complementary and Alternative Medicine (CAM) to ... the biological effects of a number of plant-derived ... as dietary supplements, on pancreatic diseases, autoimmune and ...
    ... oncology tests, SAN DIEGO, Oct. 5 AviaraDx, ... a corporate overview of its molecular,diagnostic test offerings and ... is scheduled for Thursday, November,1st, at 2:30 p.m. in ... Marriott,Del Mar Hotel, 11966 El Camino Real, San Diego, ...
    ... Texans?, AUSTIN, Texas, Oct. 5 AARP today ... of TXU amounts,to one more backroom deal that ignores ... billion in new debt for a mere,one-time $15 electric ... said Bob Jackson, AARP Texas,state director. "They,ll be the ...
    ... aren,t consuming recommended levels, experts say , , FRIDAY, Oct. ... officials warned pregnant women to eat no more than ... mercury contamination, many women have been confused, and fish ... says that that warning by the U.S. Food and ...
    Cached Medicine News:Health News:Angel Flight West Recognizes Northern California Pilots at AFW 24th Anniversary Awards 2Health News:NCCAM expands Centers of Excellence in CAM research program 2Health News:NCCAM expands Centers of Excellence in CAM research program 3Health News:AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout 2Health News:Fish Safe for Pregnant Women to Eat 2Health News:Fish Safe for Pregnant Women to Eat 3
    ... offers a complete line of flowmeters, available in oxygen, ... available in a variety of calibrations to best suit ... to the gas in use, the Amvex Flowmeter is ... the U with I. For Power Take-Off add PT ...
    ... Amvex offers a complete line of flowmeters, available in ... all available in a variety of calibrations to best ... specific to the gas in use, the Amvex Flowmeter ... replace the U with I. For Power Take-Off add ...
    ... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
    0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
    Medicine Products: